Targeting Mitochondrial PD-L1 O-GlcNAcylation to Sensitize HBV-Related HCC to Immunotherapy: Modulating Golgi-mitochondrial Crosstalk and mTOR/PGC-1α-Driven Mitochondrial Biogenesis to Overcome Resistance
International Journal of Biological Sciences · 22.07.2026 · 22 (13) · 6892-6913
DOI: 10.7150/ijbs.126948 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, erschienen am 22.07.2026. Verfasst von Ze-Bang Du und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Xiang'an Hospital of Xiamen University, National Innovatio…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, B7-H1 Antigen. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with chronic hepatitis B virus (HBV) infection representing its foremost risk factor. Although programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) have entered clinical practice, response rates in HBV-related HCC remain limited, underscoring the urgent need for mechanism-based strategies to overcome intrinsic resistance and improve immune checkpoint blockade (ICB) efficacy by exploiting noncanonical PD-L1 functions. Here, we identify a non-canonical pathway in which the HBV-encoded X protein (HBx) drives O-GlcNAcylation (O-GlcNAc) of PD-L1 at S283 and T285, thereby promoting PD-L1 mitochondrial translocation via the GOLPH3/Drp1 axis. Mitochondrial PD-L1 (mtPD-L1) hijacks Golgi-mitochondria communication to activate the mTOR/PGC-1α axis, enhance mitochondrial biogenesis and translation, and reprogram cellular energy metabolism, ultimately conferring resistance to anti-PD-L1 antibody (αPD-L1) therapy in HBV-related HCC. Pharmacological inhibition of O-GlcNAcylation with OSMI-1 disrupts this mtPD-L1 regulatory axis, restores mitochondrial homeostasis, and sensitizes HBV-related HCC to αPD-L1 therapy. Collectively, these findings identify O-GlcNAcylated mtPD-L1 as a previously unrecognized immunometabolic checkpoint and establish the mtPD-L1-mTOR/PGC-1α axis as a key mechanism linking mitochondrial biogenesis to immunotherapy resistance. This study provides a rationale for combining αPD-L1 with OSMI-1-mediated O-GlcNAcylation inhibition as a therapeutic strategy to improve immunotherapy sensitivity in HBV-related HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, Sch…
- Department of Hepatobiliary Surgery, Cancer Research Center, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China.
Zitieren
APA
Du, Z. B., Ma, X. Y., Zhang, H. Y., Lei, J. M., He, X. X., Xu, W. Q., Zhou, W. D., Xia, X. G., Zhuang, A. B., Chen, X. X., Yao, Y. L., Li, W. G., Lin, Y. C., & Lin, Z. N. (2026). Targeting Mitochondrial PD-L1 O-GlcNAcylation to Sensitize HBV-Related HCC to Immunotherapy: Modulating Golgi-mitochondrial Crosstalk and mTOR/PGC-1α-Driven Mitochondrial Biogenesis to Overcome Resistance. International Journal of Biological Sciences, 22(13), 6892-6913. https://doi.org/10.7150/ijbs.126948
Vancouver
Du ZB, Ma XY, Zhang HY, Lei JM, He XX, Xu WQ, et al. Targeting Mitochondrial PD-L1 O-GlcNAcylation to Sensitize HBV-Related HCC to Immunotherapy: Modulating Golgi-mitochondrial Crosstalk and mTOR/PGC-1α-Driven Mitochondrial Biogenesis to Overcome Resistance. International Journal of Biological Sciences. 2026;22(13):6892-6913. doi:10.7150/ijbs.126948
BibTeX
@article{Du2026,
author = {Du, Ze-Bang and Ma, Xin-Yu and Zhang, Han-Yu and Lei, Jia-Ming and He, Xin-Xin and Xu, Wen-Qi and Zhou, Wen-Dan and Xia, Xiao-Gang and Zhuang, Ao-Bo and Chen, Xiao-Xuan and Yao, You-Liang and Li, Wen-Gang and Lin, Yu-Chun and Lin, Zhong-Ning},
title = {Targeting Mitochondrial PD-L1 O-GlcNAcylation to Sensitize HBV-Related HCC to Immunotherapy: Modulating Golgi-mitochondrial Crosstalk and mTOR/PGC-1α-Driven Mitochondrial Biogenesis to Overcome Resistance},
journal = {International Journal of Biological Sciences},
year = {2026},
volume = {22},
number = {13},
pages = {6892--6913},
doi = {10.7150/ijbs.126948}
}
EUVIMED